Project 1 will generate and use mouse models for studying how exposure to hepatotoxic Superfund substances causes fatty liver disease and its different manifestations, including inflammation, fibrosis and cancer. It has become increasingly clear that exposure to many industrial and environmental toxicants can cause toxicant- associated fatty liver disease (TAFLD) and its more serious form, toxicant-associated steatohepatitis (TASH), whose pathological signs are strikingly similar to those of non-alcoholic fatty liver disease (NAFLD) and non- alcoholic stateohepatits (NASH), respectively. As the pathogenic mechanisms underlying to TAFLD and TASH are poorly understood, we posit that better insight to toxicant-induced liver diseases can be gained from studying them along with NAFLD and NASH. Moreover, pre-existing NAFLD can increase the susceptibility of the liver to toxicant induced damage, further justifying the study of this metabolic condition that can progress to NASH or TASH and then to liver cirrhosis and cancer, diseases whose incidence is greater in economically disadvantaged Indian- and Mexican-American populations. During the past project period we obtained exciting and important preliminary results according to which the development and clinical progression of NASH and TASH are strongly modulated by two different populations of B lymphocytres, spleen-derived B2 B cells that promote fibrotic progression and IgA-producing plasmocytes that attenuate the onset of liver fibrosis, but favor the establishment of an immunosuppressive microenvironment permissive to the growth and progression of hepatocellular carcinoma (HCC). Correspondingly, the specific targeting of IgA+ plasmocytes results in immune rejection of established HCC. To better understand the role of these B populations in the development and progression of NASH and TASH and to generate a new therapeutic approach to the treatment of toxicant-and obesity-induced liver cancer we will: 1) Define the pathways responsible for B cell recruitment into toxicant-damaged steatotic livers; 2) Determine how TASH and NASH trigger IgA class switch recombination (CSR) in liver-infiltrating B cells; 3) Determine how IgA+ plasmocytes attenuate NASH- and TASH-associated liver fibrosis; 4) Determine the role of T cell subsets and microbiota in the development of NASH and TASH; 5) identify secreted metabolites that along with IgA can be used for non-invasive detection of liver fibrosis; 6) determine the role of IgA+ plasmocytes in NASH and TASH progression to HCC. Our ability to accomplish these goals and gain a much better understanding of the immune mechanisms that affect the pathogenesis of NASH and TASH will be greatly enhanced by our research cores and the close collaborative interactions with other research projects.

Public Health Relevance

Approximately one third of all industrial chemicals were found to induce fatty changes in liver, turned toxicant associated fatty liver disease (TAFLD) and toxicant associated steatoheapatits (TASH), whose pathology is similar to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), metabolic disorder that greatly increase the risk of liver fibrosis/cirrhosis and liver cancer. Using mouse models of these liver diseases we will investigate the roles played by different populations of B lymphocytes in the development of toxicant and obesity induced liver fibrosis and cancer, diseases that disproportionally affect economically disadvantaged American Indians and Mexican Americans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
5P42ES010337-17
Application #
9520142
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
17
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hoffmann, Hanne M; Gong, Ping; Tamrazian, Anika et al. (2018) Transcriptional interaction between cFOS and the homeodomain-binding transcription factor VAX1 on the GnRH promoter controls Gnrh1 expression levels in a GnRH neuron maturation specific manner. Mol Cell Endocrinol 461:143-154
Zhong, Zhenyu; Liang, Shuang; Sanchez-Lopez, Elsa et al. (2018) New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560:198-203
Wei, Zong; Yoshihara, Eiji; He, Nanhai et al. (2018) Vitamin D Switches BAF Complexes to Protect ? Cells. Cell 173:1135-1149.e15
Caussy, Cyrielle; Hsu, Cynthia; Lo, Min-Tzu et al. (2018) Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology :
McNulty, Reginald; Cardone, Giovanni; Gilcrease, Eddie B et al. (2018) Cryo-EM Elucidation of the Structure of Bacteriophage P22 Virions after Genome Release. Biophys J 114:1295-1301
Song, Na-Young; Zhu, Feng; Wang, Zining et al. (2018) IKK? inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways. Proc Natl Acad Sci U S A 115:E812-E821
Song, Isabelle Jingyi; Yang, Yoon Mee; Inokuchi-Shimizu, Sayaka et al. (2018) The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer 142:81-91
Hoffmann, Hanne; Pandolfi, Erica; Larder, Rachel et al. (2018) Haploinsufficiency of Homeodomain Proteins Six3, Vax1, and Otx2, Causes Subfertility in Mice Via Distinct Mechanisms. Neuroendocrinology :
Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888
Kim, Ju Youn; Garcia-Carbonell, Ricard; Yamachika, Shinichiro et al. (2018) ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P. Cell 175:133-145.e15

Showing the most recent 10 out of 404 publications